DATA REPORT

Open Access

Novel *PTCH1* mutations in Japanese familial nevoid basal cell carcinoma syndrome

Yoji Nakase¹, Atsuko Hamada¹, Naoya Kitamura², Tsuyoshi Hata^{3,5}, Shigeaki Toratani⁴, Tetsuya Yamamoto² and Tetsuji Okamoto^{1,4}

Abstract

Nevoid basal cell carcinoma syndrome (NBCCS), also known as Gorlin syndrome, is inherited in an autosomal dominant manner and is characterized by a combination of developmental abnormalities and a predisposition to tumor formation. Hedgehog receptor Patched 1 (*PTCH1*) has been identified as the mutated gene in NBCCS. We identified the *PTCH1*_c.3298_3299insAAG_p.1099_1100insE mutation in the transmembrane region, which comprises a sterol transporter whose abnormal function is reportedly related to pathogenicity.

Nevoid basal cell carcinoma syndrome (NBCCS, OMIM: 109400), also known as Gorlin syndrome, was first reported by Gorlin and Goltz in 1960¹. NBCCS is an autosomal dominant inherited disease characterized by bifid ribs and palmar pits, as well as a predisposition to various tumors, including basal cell carcinoma (BCC), medulloblastoma, ovaryoma, cardiac fibroma, odontogenic keratocyst, and skin patch^{2–4}. At birth, patients with NBCCS typically exhibit macrocephaly or rib anomalies. As the patients' age, palmar and plantar pits become evident. At the age of approximately 10 years, an odontogenic keratocyst, formerly known as a jaw cyst, is observed as the first notable symptom in the diagnosis of NBCCS. At the age of approximately 20 years, BCC can develop at any location on the body, particularly on the eyelid. However, in Japanese patients with NBCCS, the incidence of BCC is significantly low, whereas the frequency of odontogenic keratocysts is relatively high^{3,5}.

The gene responsible for causing NBCCS is the human homologue of the *Drosophila* patched gene Patched 1 (*PTCH1*)⁶. *PTCH1*, a Hedgehog (HH) receptor, is located

on chromosome 9q22.3, consists of 23 exons, and encodes a 1447-amino-acid integral membrane protein with 12 transmembrane (TM) regions, five of which form a sterol-sensing domain and two extracellular loops at which the N-terminal domain of the HH ligand binds^{7,8}. The *PTCH1* protein functions to inhibit the transmembrane protein Smoothened (SMO). Once extracellular HH ligands bind to the *PTCH1* receptor, *PTCH1* releases SMO inhibition, allowing SMO to participate in downstream signaling and activate GLI transcription factors. HH signaling plays an essential role during embryogenesis and maintains stem cell populations in certain adult tissues^{9,10}. Unliganded *PTCH1* inhibits HH signaling; this repression is released when HH ligands bind to *PTCH1*^{7,8}. In this study, we investigated *PTCH1* germline mutations in Japanese familial NBCCS.

Patients were diagnosed with NBCCS in the Department of Oral and Maxillofacial Surgery, Kawasaki Medical University Hospital, and Hiroshima University Hospital based on both clinical and genetic analyses. Each patient in the family with NBCCS was designated F1, F2, F3, F4, F5, F6, and F7. The pedigree is shown in Fig. 1a. F1–F5 had odontogenic keratocysts. F4 and F5 had undergone surgery for removal of odontogenic keratocysts several times at the Kawasaki Medical University Hospital. F1–F7 exhibited palmar and plantar pits, F3 and F4 showed kyphoscoliosis and calcification of the falx cerebri, and F4

Correspondence: Tetsuji Okamoto (tetsuok@hiroshima-u.ac.jp)

¹Oral and Maxillofacial Surgery, Hiroshima University Hospital, Hiroshima, Japan

²Department of Oral and Maxillofacial Surgery, Kochi Medical School, Kochi University, Kochi, Japan

Full list of author information is available at the end of the article

These authors contributed equally: Yoji Nakase, Atsuko Hamada

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

Fig. 2 Direct sequencing of *PTCH1* in familial nevoid basal cell carcinoma syndrome (NBCCS). The results of direct sequencing of *PTCH1* exon 19 are shown. Though an insertion was not detected in WT, an AAG insertion was detected between coding sequences 3298 and 3299 in F4–F7.

had BCC, skin patch, and hairy skin patch. F6 and F7 had a congenital deficiency of the second premolar. Based on interviews with the patients, the husband of F5 also had a deficiency of the second premolar, and his mother had congenital deficiency of several incisors. The main phenotypes of F1–F7 are shown in Fig. 1b.

We detected irregular band shifts in exon 19 in F1–F5 through PCR-SSCP (data not shown). Direct sequencing revealed the c.3298_3299insAAG mutation in exon 19 of *PTCH1* in F1–F7 (Fig. 2). To screen for other pathogenic mutations affecting the HH signaling pathway, we performed NGS with the MiSeq sequencer using the TruSight One panel for familial NBCCS and identified the following mutations: *PTCH1*_c.1665T>C_p.N555N (exon 12), _c.2560+9G>C (intron 15), _c.2887+21G>A (intron 17), _c.3298_3299insAAG_p.1099_1100insE (exon 19), and _c.3944C>T_p.P1315L (exon 23). Among the detected mutations, only *PTCH1*_c.3298_3299insAAG_p.1099_1100insE was specifically shared in our cases of familial NBCCS (F1–F7) and was not shared in WT1–WT4 (Fig. 1c). In contrast, there were no other pathogenic mutations in HH signaling-related molecules, such as *PTCH2*, *SHH*, *SMO*, *SUFU*, *GLI1*, *GLI2*, and *GLI3*.

The detected mutation, *PTCH1*_c.3298_3299insAAG_p.1099_1100insE, was located in the 10th transmembrane region and mapped closely to sterol-binding sites. Recently, through structure-guided mutational analysis, Gong *et al.* revealed that the interaction between Shh-N and *PTCH1* is steroid-dependent¹¹. Moreover, *PTCH1*_c.3298_3299insAAG was not found in Togo Var,

Exome Variant Server, dbSNP, dbVar, or ClinVar, confirming that the mutation is novel. In addition, *PTCH1*_c.3298_3299insAAG was predicted as disease causing by Mutation Taster2 and as deleterious by PROVEAN software. Thus, we predicted that the specifically shared mutation, *PTCH1*_c.3298_3299insAAG_p.1099_1100insE, would be responsible for the pathogenesis of NBCCS^{11,12}.

Of note, c.1665T>C (rs1805155), located in a sterol-sensing domain, is synonymous and the most common SNP in *PTCH1*. Clinical significance is benign in ClinVar. To our knowledge, there is no prior report about the pathogenicity of this SNP. c.2560+9G>C and c.2887+21G>A are intronic SNPs. Although c.2887+21G>A is not reported, c.2560+9G>C (rs2066829) is registered as an intronic variant and benign in ClinVar. It is unknown whether the *PTCH1* polymorphisms located in introns cause a functional change. However, intronic polymorphisms have been demonstrated in association with other complex diseases, including the association of IRF6 with cleft lip/palate^{13,14}. c.3944C>T (rs357564) results in an amino acid change in the topological domain of the C-terminus of *PTCH1*. Though the interpretation is benign in ClinVar, some researchers have concluded that, in combination with oral contraceptive use, c.3944C>T-carrier in *PTCH1* is associated with an increased risk of breast cancer¹⁵. Because *PTCH1* has a sterol-sensing domain, long-term exogenous hormone use is reportedly related to breast cancer risk. Although the above three SNPs were also detected in wild-type *PTCH1* in this

family, it was recently suggested that SNPs in key genes involved in the HH signaling pathway are associated with susceptibility to odontogenic cystic lesions¹⁶.

Here, we reported the detection of a novel mutation, PTCH1_c.3298_3299insAAG_p.1099_1100insE, in Japanese familial NBCCS. Therefore, we conclude that PTCH1_c.3298_3299insAAG is the “likely pathogenic” mutation of NBCCS.

HGV Database

The relevant data from this Data Report are hosted at the Human Genome Variation Database at <https://doi.org/10.6084/m9.figshare.hgv.2927>.

Acknowledgements

The authors would like to thank all individuals who participated in this study. This work was carried out in part at the Natural Science Center for Basic Research and Development, Hiroshima University. This research was financially supported by the Grant-in-Aid for Scientific Research (B) to T.O. (Grant number: 18H03000), Grant-in-Aid for Young Scientists to Y.N. (20K18725), Grant-in-Aid for Young Scientists to A.H. (19K191980A), and Grant-in-Aid for Scientific Research (C) to S.T. (18K097440A) from the Japanese Ministry of Education, Culture, Sports, Science and Technology.

Author details

¹Oral and Maxillofacial Surgery, Hiroshima University Hospital, Hiroshima, Japan. ²Department of Oral and Maxillofacial Surgery, Kochi Medical School, Kochi University, Kochi, Japan. ³Department of Oral Surgery, Kawasaki Medical School, Okayama, Japan. ⁴Department of Molecular Oral Medicine and Maxillofacial Surgery, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan. ⁵Present address: Kondo Dental Clinic, Medical Corporation Mutsumikai, Okayama, Japan

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This study was approved by the Ethics Committee of Human Genome/Gene Analysis Research at Hiroshima University (approval number: hi-72). All participants provided informed consent prior to their inclusion in this study.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 18 September 2020 Revised: 20 October 2020 Accepted: 22 October 2020.

Published online: 18 November 2020

References

- Gorlin, R. J. & Goltz, R. W. Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib. A syndrome. *N. Engl. J. Med.* **262**, 908–912 (1960).
- Fujii, K. et al. Mutations in the human homologue of Drosophila patched in Japanese nevoid basal cell carcinoma syndrome patients. *Hum. Mutat.* **21**, 451–452 (2003).
- Fujii, K. & Miyashita, T. Gorlin syndrome (nevoid basal cell carcinoma syndrome): update and literature review. *Pediatr. Int.* **56**, 667–674 (2014).
- Wilson, L. C., Ajayi-Obe, E., Bernhard, B. & Maas, S. M. Patched mutations and hairy skin patches: a new sign in Gorlin syndrome. *Am. J. Med. Genet. A* **140**, 2625–2630 (2006).
- Johnson, R. L. et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. *Science* **272**, 1668–1671 (1996).
- Marigo, V., Davey, R. A., Zuo, Y., Cunningham, J. M. & Tabin, C. J. Biochemical evidence that patched is the Hedgehog receptor. *Nature* **384**, 176–179 (1996).
- Stone, D. M. et al. The tumour-suppressor gene patched encodes a candidate receptor for Sonic hedgehog. *Nature* **384**, 129–134 (1996).
- Kato, C. et al. Nevoid basal cell carcinoma syndrome caused by splicing mutations in the PTCH1 gene. *Fam. Cancer* **16**, 131–138 (2017).
- McMahon, A. P., Ingham, P. W. & Tabin, C. J. Developmental roles and clinical significance of hedgehog signaling. *Curr. Top. Dev. Biol.* **53**, 1–114 (2003).
- Varjosalo, M. & Taipale, J. Hedgehog: functions and mechanisms. *Genes Dev.* **22**, 2454–2472 (2008).
- Gong, X. et al. Structural basis for the recognition of Sonic Hedgehog by human Patched 1. *Science* **361**, eaas8935 (2018).
- Kowatsch, C., Woolley, R. E., Kinnebrew, M., Rohatgi, R. & Siebold, C. Structures of vertebrate Patched and Smoothened reveal intimate links between cholesterol and Hedgehog signalling. *Curr. Opin. Struct. Biol.* **57**, 204–214 (2019).
- Zuccherro, T. M. et al. Interferon regulatory factor 6 (IRF6) gene variants and the risk of isolated cleft lip or palate. *N. Engl. J. Med.* **351**, 769–780 (2004).
- Letra, A. et al. Follow-up association studies of chromosome region 9q and nonsyndromic cleft lip/palate. *Am. J. Med. Genet. A* **152A**, 1701–1710 (2010).
- Chang-Claude, J. et al. The patched polymorphism Pro1315Leu (C3944T) may modulate the association between use of oral contraceptives and breast cancer risk. *Int. J. Cancer* **103**, 779–783 (2003).
- Magic, M. et al. Hedgehog signaling pathway and vitamin D receptor gene variants as potential risk factors in odontogenic cystic lesions. *Clin. Oral. Invest.* **23**, 2675–2684 (2019).